Fulltext

Reduced 11β‐hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome

Vogt, Bruno ; Dick, Bernhard ; Marti, Hans‐Peter ; Frey, Felix J. ; Frey, Brigitte M.

In: Nephrology Dialysis Transplantation, 2002, vol. 17, no. 5, p. 753-758

Ajouter à la liste personnelle
    Titre
    • Reduced 11β‐hydroxysteroid dehydrogenase activity in experimental nephrotic syndrome
    Auteur
    • Vogt, Bruno. Division of Nephrology and Hypertension, University Hospital of Berne, Inselspital, Berne, Switzerland
    • Dick, Bernhard. Division of Nephrology and Hypertension, University Hospital of Berne, Inselspital, Berne, Switzerland
    • Marti, Hans‐Peter. Division of Nephrology and Hypertension, University Hospital of Berne, Inselspital, Berne, Switzerland
    • Frey, Felix J.. Division of Nephrology and Hypertension, University Hospital of Berne, Inselspital, Berne, Switzerland
    • Frey, Brigitte M.. Division of Nephrology and Hypertension, University Hospital of Berne, Inselspital, Berne, Switzerland
    Type de document
    • Postprint
    Langue
    • Anglais
    Publié dans
    • Nephrology Dialysis Transplantation, 2002, vol. 17, no. 5, p. 753-758. Oxford University Press
    Autre version électronique
    Identifiant OAI-PMH
    • oai:doc.rero.ch:300342
    Summary
    Background. The disease state of the nephrotic syndrome is characterized by abnormal renal sodium retention that cannot be completely explained by a secondary hyperaldosteronism for the following reasons. Firstly, in rats an enhanced sodium retention is observed before proteinuria with intravascular volume depletion occurs. Secondly, in patients with the nephrotic syndrome, volume expansion with hypertension has been reported despite suppression of the renin‐aldosterone system. Therefore, another mechanism for sodium retention must be postulated for this disease state. We hypothesize that this mechanism is a reduced 11β‐hydroxysteroid dehydrogenase 2 (11β‐HSD2) activity, a phenomenon known to cause enhanced access of cortisol or corticosterone to the mineralocorticoid receptor. Methods. We assessed the 11β‐HSD activity by measuring the urinary ratio of tetrahydrocorticosterone (THB) plus 5α‐tetrahydrocorticosterone (5α‐THB) to 11‐dehydro‐tetrahydrocorticosterone (THA) by gas chromatography-mass spectrometry in rats with puromycin aminonucleoside (PAN)‐induced proteinuria and with adriamycin nephrosis. Furthermore, the plasma ratios of corticosterone to 11‐dehydrocorticosterone were measured. Results. The urinary ratio of (THB+5α‐THB)/THA increased in all animals following injection of PAN or adriamycin, indicating a reduced activity of 11β‐HSD. The reduced activity of 11β‐HSD was confirmed by an increased plasma ratio of corticosterone to 11‐dehydrocorticosterone. The changes in the glucocorticoid metabolite ratios were already present before significant proteinuria appeared. Conclusion. PAN‐ or adriamycin‐treated rats develop proteinuria with a reduced activity of 11β‐HSD, a mechanism contributing to the abnormal sodium retention in nephrotic syndrome